PerkinElmer, Inc. (NYSE:PKI) insider Andrew Okun sold 2,273 shares of PerkinElmer stock in a transaction that occurred on Monday, February 5th. The shares were sold at an average price of $77.86, for a total transaction of $176,975.78. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Andrew Okun also recently made the following trade(s):

  • On Friday, December 15th, Andrew Okun sold 12,680 shares of PerkinElmer stock. The stock was sold at an average price of $72.00, for a total transaction of $912,960.00.

PerkinElmer, Inc. (NYSE:PKI) opened at $72.06 on Friday. The company has a current ratio of 1.27, a quick ratio of 0.90 and a debt-to-equity ratio of 0.72. PerkinElmer, Inc. has a 52-week low of $53.16 and a 52-week high of $84.49. The stock has a market cap of $8,351.76, a PE ratio of 25.95, a price-to-earnings-growth ratio of 1.75 and a beta of 0.76.

PerkinElmer (NYSE:PKI) last released its earnings results on Thursday, January 25th. The medical research company reported $0.97 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.94 by $0.03. PerkinElmer had a net margin of 12.97% and a return on equity of 13.30%. The company had revenue of $641.63 million for the quarter, compared to the consensus estimate of $619.14 million. During the same period in the prior year, the company posted $0.83 EPS. The company’s revenue was up 13.2% compared to the same quarter last year. equities research analysts anticipate that PerkinElmer, Inc. will post 3.52 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 10th. Investors of record on Friday, April 13th will be given a $0.07 dividend. The ex-dividend date is Thursday, April 12th. This represents a $0.28 dividend on an annualized basis and a dividend yield of 0.39%. PerkinElmer’s dividend payout ratio is 10.61%.

Several equities analysts recently commented on the stock. Robert W. Baird reiterated a “buy” rating and set a $88.00 target price on shares of PerkinElmer in a research note on Friday, January 26th. Zacks Investment Research raised shares of PerkinElmer from a “hold” rating to a “buy” rating and set a $86.00 target price on the stock in a report on Monday, January 8th. Cowen reaffirmed a “hold” rating and issued a $84.00 target price on shares of PerkinElmer in a report on Friday, January 26th. Jefferies Group reiterated a “hold” rating and set a $70.00 price target on shares of PerkinElmer in a research report on Friday, October 20th. Finally, ValuEngine downgraded shares of PerkinElmer from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. One research analyst has rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the stock. PerkinElmer has an average rating of “Hold” and a consensus price target of $76.85.

Large investors have recently made changes to their positions in the stock. Cutler Group LP raised its position in shares of PerkinElmer by 845.7% in the 4th quarter. Cutler Group LP now owns 2,237 shares of the medical research company’s stock valued at $163,000 after acquiring an additional 2,537 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its position in shares of PerkinElmer by 53.8% in the 4th quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 2,228 shares of the medical research company’s stock valued at $170,000 after acquiring an additional 779 shares during the period. Waldron LP acquired a new stake in shares of PerkinElmer in the 3rd quarter valued at approximately $200,000. Seaward Management Limited Partnership acquired a new stake in shares of PerkinElmer in the 3rd quarter valued at approximately $202,000. Finally, Signition LP acquired a new stake in shares of PerkinElmer in the 4th quarter valued at approximately $207,000. Institutional investors and hedge funds own 90.98% of the company’s stock.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Daily Political and is owned by of Daily Political. If you are accessing this piece of content on another website, it was illegally stolen and reposted in violation of United States & international copyright law. The correct version of this piece of content can be read at https://www.dailypolitical.com/2018/02/09/perkinelmer-inc-pki-insider-andrew-okun-sells-2273-shares-of-stock.html.

About PerkinElmer

PerkinElmer, Inc is a provider of products, services and solutions to the diagnostics, research, environmental, industrial and laboratory services markets. The Company operates through two segments: Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment serves the environmental, food, industrial, life sciences research and laboratory services markets.

Insider Buying and Selling by Quarter for PerkinElmer (NYSE:PKI)

Receive News & Ratings for PerkinElmer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PerkinElmer and related companies with MarketBeat.com's FREE daily email newsletter.